Akoya Biosciences, Inc. AKYA
Set alert
At close · Jul 8
- Open
- 1.29
- Prev close
- 1.29
- Mkt cap
- 119.45M
- Vol
- 715.25K
- Avg vol
- 233.37K
- EPS
- -1.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.29
- High
- 1.29
- Forward P/E
- -4.38
- Beta
- 1.35
- Short ratio
- 13.43
- Inst. own
- 70.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 5, 2024
- 50-d avg
- 2.63
- 200-d avg
- 2.91
- 1y target
- 3.50
Key statistics
- Market cap
- 119.45M
- Enterprise value
- 194.41M
- Trailing P/E
- 0.00
- Forward P/E
- -4.38
- PEG ratio
- 0.00
- Price / sales
- 1.28
- Price / book
- 2.20
- EPS (TTM)
- -1.16
- Beta
- 1.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -64.74%
- Revenue (TTM)
- 93.22M
- Revenue growth
- -1.50%
- Free cash flow
- -34.91M
- Total cash
- 45.22M
- Total debt
- 84.70M
- Return on equity
- -128.20%
- Shares outstanding
- 49.56M
- Short % of float
- 5.34%
- 50-day average
- 2.63
- 200-day average
- 2.91
Analyst view
Consensus: none
- Target (low)
- 3.00
- Target (mean)
- 3.50
- Target (high)
- 5.00
- Strong buy1
- Buy2
- Hold5
- Sell0
- Strong sell0
Next earnings
Aug 5, 2024
Expected Aug 5, 2024. Consensus EPS estimate -0.16248.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.19 | -0.18 | +0.01 | +5.26% |
| Aug 5, 2024 | Jun 1, 2024 | -0.27 | -0.27 | 0.00 | 0.00% |
| Aug 5, 2024 | Jun 1, 2024 | -0.27 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.30 | -0.35 | -0.05 | -16.67% |
| May 13, 2024 | Mar 1, 2024 | -0.30 | — | — | — |
| Mar 4, 2024 | Dec 1, 2023 | -0.27 | -0.22 | +0.05 | +18.52% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | Piper Sandler | reit | Overweight | Overweight |
| Nov 15, 2024 | Craig-Hallum | down | Buy | Hold |
| Nov 15, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 13, 2024 | Piper Sandler | main | Overweight | Overweight |
| Aug 6, 2024 | Morgan Stanley | down | Overweight | Equal-Weight |
| Aug 6, 2024 | BTIG | down | Buy | Neutral |
About Akoya Biosciences, Inc.
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- akoyabio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on AKYA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAMFORD PASCAL | Officer | Stock Award(Grant) | Nov 18, 2024 | 210,258 |
| EK JOHN FREDERICK | Chief Financial Officer | Stock Award(Grant) | Nov 18, 2024 | 288,228 |
| KAMOCSAY JENNIFER | Officer | Stock Award(Grant) | Nov 18, 2024 | 186,717 |
| MCKELLIGON BRIAN M | Chief Executive Officer | Stock Award(Grant) | Nov 18, 2024 | 443,483 |
| MENDEL SCOTT | Director | Purchase | Jun 11, 2023 | 28,500 |
| PLA FREDERIC | Chief Operating Officer | Stock Award(Grant) | Feb 21, 2024 | 123,506 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blue Water Life Science Advisors, Lp | 9.48% | 4,697,785 | 11.32M | Sep 29, 2024 |
| Blackrock Inc. | 3.19% | 1,580,164 | 3.81M | Sep 29, 2024 |
| Vanguard Group Inc | 3.00% | 1,484,973 | 3.58M | Sep 29, 2024 |
| Paragon Associates & Paragon Associates Ii Joint Venture | 1.59% | 790,000 | 1.90M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.13% | 561,609 | 1.35M | Sep 29, 2024 |
| State Street Corporation | 0.91% | 453,296 | 1.09M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.78% | 882,321 | 2.13M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.31% | 649,386 | 1.57M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.62% | 306,112 | 737.73K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.55% | 271,493 | 654.30K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.43% | 212,338 | 511.73K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.26% | 127,002 | 306.07K | Oct 30, 2024 |